3 results
Approved WMOCompleted
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.
Approved WMOCompleted
The aim of the study is:- To find simple clinical and/or laboratory parameters to predict the development of hypertension during treatment with the tyrosine kinase inhibitor Sunitinib. If such parameters are present it will be evaluated…
Approved WMOCompleted
To assess the influence of dosing guided by AutoK on achieving PK targets and clinical endpoints in intensive care patients with sepsis.